60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study

60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study

•This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2020-06, Vol.190, p.60-61
Hauptverfasser: He, Meijiao, Zhang, Yun, Yan, Wei, Liu, Guangzhong, Sun, Danghui, Yuan, Yue, Shi, Jing, Kong, Yihui, Li, Yue
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 61
container_issue
container_start_page 60
container_title Thrombosis research
container_volume 190
creator He, Meijiao
Zhang, Yun
Yan, Wei
Liu, Guangzhong
Sun, Danghui
Yuan, Yue
Shi, Jing
Kong, Yihui
Li, Yue
description •This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.
doi_str_mv 10.1016/j.thromres.2020.03.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2391974699</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049384820300876</els_id><sourcerecordid>2391974699</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-b28e918bc59cd900188660f67140e90d0ec39bfd821646b916a4833f0581e4f93</originalsourceid><addsrcrecordid>eNqFUcuO1DAQtBCIHRZ-YeUjBxLsOOPYnFiNeEkrcYGzldidSY8Se7A9g4av4Qf4Cb4MD7PLlVPL7qquri5CbjirOePy9a7OUwxLhFQ3rGE1EzXj7SOy4qrTVdN2zWOyYqzVlVCtuiLPUtoxxjuu10_JlWhEaXG-Ir8k-_1z2VIXEtCMtt9GmEOk-xiO6CDRlGPwWyg_c59hhkzRTzhgxuBpnnpP7Rz26MKZWHp0M6GHMmzfZwSfE_2OeaK2bOvRUhtK7eOJppN3xQC8obc09t6FBX-Ae0UT-u0M1TCjLy8bQ0rhWORTPrjTc_Jk7OcEL-7rNfn6_t2Xzcfq7vOHT5vbu8oKqXI1NAo0V4Nda-t0sa2UlGyUHW8ZaOYYWKGH0amGy1YOmsu-VUKMbK04tKMW1-TlZW45w7cDpGwWTBbmufcQDsk0QnPdtVKfofIC_btqhNHsIy7FoeHMnKMyO_MQlTlHZZgwJapCvLnXOAwLuH-0h2wK4O0FAMXpESGaZMtFLTiMYLNxAf-n8QfAmq2I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2391974699</pqid></control><display><type>article</type><title>60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>He, Meijiao ; Zhang, Yun ; Yan, Wei ; Liu, Guangzhong ; Sun, Danghui ; Yuan, Yue ; Shi, Jing ; Kong, Yihui ; Li, Yue</creator><creatorcontrib>He, Meijiao ; Zhang, Yun ; Yan, Wei ; Liu, Guangzhong ; Sun, Danghui ; Yuan, Yue ; Shi, Jing ; Kong, Yihui ; Li, Yue</creatorcontrib><description>•This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/j.thromres.2020.03.014</identifier><identifier>PMID: 32304911</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><ispartof>Thrombosis research, 2020-06, Vol.190, p.60-61</ispartof><rights>2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-b28e918bc59cd900188660f67140e90d0ec39bfd821646b916a4833f0581e4f93</citedby><cites>FETCH-LOGICAL-c368t-b28e918bc59cd900188660f67140e90d0ec39bfd821646b916a4833f0581e4f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.thromres.2020.03.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32304911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Meijiao</creatorcontrib><creatorcontrib>Zhang, Yun</creatorcontrib><creatorcontrib>Yan, Wei</creatorcontrib><creatorcontrib>Liu, Guangzhong</creatorcontrib><creatorcontrib>Sun, Danghui</creatorcontrib><creatorcontrib>Yuan, Yue</creatorcontrib><creatorcontrib>Shi, Jing</creatorcontrib><creatorcontrib>Kong, Yihui</creatorcontrib><creatorcontrib>Li, Yue</creatorcontrib><title>60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>•This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.</description><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFUcuO1DAQtBCIHRZ-YeUjBxLsOOPYnFiNeEkrcYGzldidSY8Se7A9g4av4Qf4Cb4MD7PLlVPL7qquri5CbjirOePy9a7OUwxLhFQ3rGE1EzXj7SOy4qrTVdN2zWOyYqzVlVCtuiLPUtoxxjuu10_JlWhEaXG-Ir8k-_1z2VIXEtCMtt9GmEOk-xiO6CDRlGPwWyg_c59hhkzRTzhgxuBpnnpP7Rz26MKZWHp0M6GHMmzfZwSfE_2OeaK2bOvRUhtK7eOJppN3xQC8obc09t6FBX-Ae0UT-u0M1TCjLy8bQ0rhWORTPrjTc_Jk7OcEL-7rNfn6_t2Xzcfq7vOHT5vbu8oKqXI1NAo0V4Nda-t0sa2UlGyUHW8ZaOYYWKGH0amGy1YOmsu-VUKMbK04tKMW1-TlZW45w7cDpGwWTBbmufcQDsk0QnPdtVKfofIC_btqhNHsIy7FoeHMnKMyO_MQlTlHZZgwJapCvLnXOAwLuH-0h2wK4O0FAMXpESGaZMtFLTiMYLNxAf-n8QfAmq2I</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>He, Meijiao</creator><creator>Zhang, Yun</creator><creator>Yan, Wei</creator><creator>Liu, Guangzhong</creator><creator>Sun, Danghui</creator><creator>Yuan, Yue</creator><creator>Shi, Jing</creator><creator>Kong, Yihui</creator><creator>Li, Yue</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200601</creationdate><title>60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study</title><author>He, Meijiao ; Zhang, Yun ; Yan, Wei ; Liu, Guangzhong ; Sun, Danghui ; Yuan, Yue ; Shi, Jing ; Kong, Yihui ; Li, Yue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-b28e918bc59cd900188660f67140e90d0ec39bfd821646b916a4833f0581e4f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Meijiao</creatorcontrib><creatorcontrib>Zhang, Yun</creatorcontrib><creatorcontrib>Yan, Wei</creatorcontrib><creatorcontrib>Liu, Guangzhong</creatorcontrib><creatorcontrib>Sun, Danghui</creatorcontrib><creatorcontrib>Yuan, Yue</creatorcontrib><creatorcontrib>Shi, Jing</creatorcontrib><creatorcontrib>Kong, Yihui</creatorcontrib><creatorcontrib>Li, Yue</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Meijiao</au><au>Zhang, Yun</au><au>Yan, Wei</au><au>Liu, Guangzhong</au><au>Sun, Danghui</au><au>Yuan, Yue</au><au>Shi, Jing</au><au>Kong, Yihui</au><au>Li, Yue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>190</volume><spage>60</spage><epage>61</epage><pages>60-61</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><abstract>•This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>32304911</pmid><doi>10.1016/j.thromres.2020.03.014</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0049-3848
ispartof Thrombosis research, 2020-06, Vol.190, p.60-61
issn 0049-3848
1879-2472
language eng
recordid cdi_proquest_miscellaneous_2391974699
source ScienceDirect Journals (5 years ago - present)
title 60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A58%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=60%C2%A0mg%20dose%20ticagrelor%20provides%20stronger%20platelet%20inhibition%20than%20clopidogrel%20in%20Chinese%20patients%20with%20chronic%20coronary%20syndrome:%20A%20randomized,%20single-blind,%20crossover%20study&rft.jtitle=Thrombosis%20research&rft.au=He,%20Meijiao&rft.date=2020-06-01&rft.volume=190&rft.spage=60&rft.epage=61&rft.pages=60-61&rft.issn=0049-3848&rft.eissn=1879-2472&rft_id=info:doi/10.1016/j.thromres.2020.03.014&rft_dat=%3Cproquest_cross%3E2391974699%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2391974699&rft_id=info:pmid/32304911&rft_els_id=S0049384820300876&rfr_iscdi=true